abemaciclib,ribociclib,palbociclib
novartis,pfizer,eli lilly,medsir
['maintain trial', 'abemaciclib', 'ribociclib', 'palbociclib', 'medsir']
great talk by on the maintain trial
-mpfs 5.3 vs 2.7 months (hr0.57) for ribo+et vs pbo+et -86% received prior palbociclib; 10% ribociclib; 4% abemaciclib -no benefit in pts w/ esr1 mutation -#palmira randomized phase 2 is looking at the same question #asco22 
Bring your idea to life?? 
Creating successful IITs & optimizing drug development ?? 
Medica Scientia Innovation Research
 ????&????
https://t.co/yp3O5Lylqc